- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Sanofi Reports LixiLan-L Topline Results; Says Combo Superior to Insulin Alone
Regulatory filings with the FDA are expected before the end of the year.
A combination of insulin glargine and the lixisenatide, a GLP-1 receptor agonist, showed superior results in helping patients with type 2 diabetes (T2D) control glycated hemoglobin (A1C) in a phase 3 trial, Sanofi reported today.
Sanofi released topline results of LixiLan-L, saying that the second pivotal trial for the drug combination met its primary endpoint. The study examined the efficacy and safety of a fixed-ratio combination of insulin glargine (Lantus), 100 units/mL, and lixisenatide versus treatment with insulin glargine 100 units/mL over a 30-week period. The study involved 736 patients with T2D whose A1C was not adequately controlled with basal insulin, either alone or in combination with 1 or 2 oral anti-diabetic agents. If patients were already taking metformin, that therapy was continued.
In July, Sanofi announced that the primary endpoint had been achieved in its first pivotal trial, LixiLan-O, which involved 1170 patients over a 30-week period. That trial involved patients whose T2D was not adequately controlled on metformin or metformin and another oral antidiabetic agent. In June, long-term cardiovascular (CV) results for lixisenatide were presented at the 75th Scientific Sessions of the American Diabetes Association, showing no CV risk or benefit.
In a statement, Sanofi said it expects to make regulatory submissions in the fourth quarter of 2015 with the FDA and in the first quarter of 2016 in Europe.
Intensive Blood Pressure Regimen Lowers CVD Risk for People With Diabetes
November 19th 2024Reducing systolic blood pressure to less than 120 mmHg lowered the risk of major cardiovascular events for most people with type 2 diabetes in the Blood Pressure Control Target in Diabetes trial.
Read More
Exploring Pharmaceutical Innovations, Trust, and Access With CVS Health's CMO
July 11th 2024On this episode of Managed Care Cast, we're talking with the chief medical officer of CVS Health about recent pharmaceutical innovations, patient-provider relationships, and strategies to reduce drug costs.
Listen
Contributor: The Diabetes Vendor Resource Guide—A Useful Directory for Employers
November 13th 2024Employees living with diabetes often face unique challenges, such as managing blood sugar levels, balancing medication, and preventing complications, all while maintaining their professional responsibilities. This condition can lead to increased absenteeism, reduced productivity, and rising health care costs.
Read More
How Can Employers Leverage the DPP to Improve Diabetes Rates?
February 15th 2022On this episode of Managed Care Cast, Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains the Coalition’s efforts to reduce diabetes rates through the Diabetes Prevention Program (DPP).
Listen
